StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO)

StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a report released on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, Alliance Global Partners began coverage on Aptevo Therapeutics in a research report on Monday, October 9th. They set a buy rating for the company.

Aptevo Therapeutics Stock Up 6.3 %

Shares of NASDAQ:APVO opened at $0.20 on Friday. The business has a fifty day simple moving average of $0.30 and a 200-day simple moving average of $0.85. Aptevo Therapeutics has a 52 week low of $0.15 and a 52 week high of $7.20.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.14. On average, equities analysts forecast that Aptevo Therapeutics will post -2.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Sabby Management LLC acquired a new position in shares of Aptevo Therapeutics during the third quarter worth about $440,000. Armistice Capital LLC acquired a new position in shares of Aptevo Therapeutics during the third quarter worth about $408,000. Cantor Fitzgerald L. P. lifted its stake in shares of Aptevo Therapeutics by 14.8% during the second quarter. Cantor Fitzgerald L. P. now owns 251,122 shares of the biotechnology company’s stock worth $367,000 after purchasing an additional 32,422 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Aptevo Therapeutics by 45.8% during the second quarter. Renaissance Technologies LLC now owns 80,186 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 25,200 shares in the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Aptevo Therapeutics during the fourth quarter worth about $29,000. Institutional investors and hedge funds own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.